GenKyoTex S.A. Receives FDA IND Approval for Phase II Clinical Study With First in Class NOX Inhibitor GKT137831
Published: Sep 09, 2013
GENEVA & ARCHAMPS, France--(BUSINESS WIRE)--Genkyotex, the leading developer of NOX enzyme inhibitors, announced today that the U.S. Food and Drug Administration has approved the company’s Investigational New Drug (IND) application to begin a Phase II clinical study of GKT137831 in patients with diabetic nephropathy. GKT137831 is a first in class inhibitor targeting NOX1 and NOX4 enzymes. Enrollment of patients into the multinational Phase II study is expected to begin during Q4, 2013.
Help employers find you! Check out all the jobs and post your resume.